Abstract
Background
Dual orexin receptor antagonists (DORAs) enable initiation and maintenance of sleep in patients with primary insomnia. Blockade of the orexin system has shown reduction of drug-seeking behavior in animal studies, supporting the role of orexin antagonism as a novel approach for treating substance abuse. Since hypnotics are traditionally associated with misuse, a lack of abuse liability of DORAs would offer significant benefits over current therapies for sleep disorders.
Methods
In this randomized, crossover, proof-of-concept study, single oral doses of the DORA almorexant (200, 400, and 1,000 mg) were administered to healthy subjects with previous non-therapeutic experience with central nervous system depressants and were compared with placebo and single oral doses of zolpidem (20 and 40 mg), a benzodiazepine-like drug. Subjective measures of abuse potential (visual analog scales [VAS], Addiction Research Center Inventory, and Subjective Drug Value) and objective measures (divided attention [DA]) were evaluated over 24 h post-dose in 33 evaluable subjects.
Results
Drug Liking VAS peak effect (E max; primary endpoint) was significantly higher for all doses of almorexant and zolpidem compared with placebo (p < 0.001). Almorexant 200 mg showed significantly less ‘Drug Liking’ than both zolpidem doses (p < 0.01), and almorexant 400 mg had smaller effects than zolpidem 20 mg (p < 0.05), while almorexant 1,000 mg was not different from either zolpidem dose. Results were similar for other subjective measures, although almorexant generally showed smaller negative and perceptual effects compared with zolpidem. Almorexant also showed less cognitive impairment compared with zolpidem on most DA endpoints.
Conclusion
This study in humans investigating single doses of almorexant is the first to explore and show abuse liability of a DORA, a class of compounds that is not only promising for the treatment of sleep disorders, but also of addiction.
Similar content being viewed by others
References
Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24(11):1577–601.
Licata SC, Rowlett JK. Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond. Pharmacol Biochem Behav. 2008;90(1):74–89.
Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry. 2005;66(Suppl 9):31–41.
Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med. 2007;13(2):150–5.
Hoever P, Dorffner G, Benes H, et al. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin Pharmacol Ther. 2012;91(6):975–85.
Hoever P, de Haas SL, Dorffner G, et al. Orexin receptor antagonism: an ascending multiple-dose study with almorexant. J Psychopharmacol. 2012;26(8):1071–80.
Steiner MA, Lecourt H, Strasser DS, et al. Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-alpha1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat. Neuropsychopharmacology. 2011;36(4):848–56.
Hoch M, Hay JL, Hoever P, et al. Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans. Eur Neuropsychopharmacol. 2013;23(2):107–17.
Steiner MA, Lecourt H, Jenck F. The dual orexin receptor antagonist almorexant, alone and in combination with morphine, cocaine and amphetamine, on conditioned place preference and locomotor sensitization in the rat. Int J Neuropsychopharmacol. 2013;16(2):417–32.
Brisbare-Roch C, Fischer W, Jenck F. Effect of once-daily almorexant treatment for 6 weeks on the sleep–wake cycle of normal Wistar rats. Eur Neuropsychopharmacol. 2010;20(Suppl 3):S253–4.
Actelion Pharmaceuticals Ltd. Almorexant (ACT-078573) in adult subjects with chronic primary insomnia (RESTORA1) [ClinicalTrials.gov identifier NCT00608985]. US National Institutes of Health, ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00608985?term=restora&rank=1.
Mahler SV, Smith RJ, Moorman DE, et al. Multiple roles for orexin/hypocretin in addiction. Prog Brain Res. 2012;198:79–121.
Kim AK, Brown RM, Lawrence AJ. The role of orexins/hypocretins in alcohol use and abuse: an appetitive-reward relationship. Front Behav Neurosci. 2012;6:78.
Srinivasan S, Simms JA, Nielsen CK, et al. The dual orexin/hypocretin receptor antagonist, almorexant, in the ventral tegmental area attenuates ethanol self-administration. PLoS One. 2012;7(9):e44726.
LeSage MG, Perry JL, Kotz CM, et al. Nicotine self-administration in the rat: effects of hypocretin antagonists and changes in hypocretin mRNA. Psychopharmacology (Berl). 2010;209(2):203–12.
O’Connor EC, Chapman K, Butler P, et al. The predictive validity of the rat self-administration model for abuse liability. Neurosci Biobehav Rev. 2011;35(3):912–38.
Bardo MT, Bevins RA. Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology (Berl). 2000;153(1):31–43.
Riegel AC, Kalivas PW. Neuroscience: lack of inhibition leads to abuse. Nature. 2010;463(7282):743–4.
Tan KR, Brown M, Labouebe G, et al. Neural bases for addictive properties of benzodiazepines. Nature. 2010;463(7282):769–74.
Schoedel KA, Sellers EM. Assessing abuse liability during drug development: changing standards and expectations. Clin Pharmacol Ther. 2008;83(4):622–6.
Griffiths RR, Bigelow GE, Ator NA. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. 2003;70(3 Suppl):S41–54.
Chen L, Tsong Y. Design and analysis for drug abuse potential studies: issues and strategies for implementing a crossover design. Drug Inf J. 2007;41(4):481–9.
Center for Drug Evaluation and Research, Food and Drug Administration. Assessment of abuse potential of drugs (draft guidance). Guidance for industry. Jan 2010.
Parasrampuria DA, Schoedel KA, Schuller R, et al. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol. 2007;27(5):459–67.
Bowdle TA, Radant AD, Cowley DS, et al. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology. 1998;88(1):82–8.
Martin WR, Sloan JW, Sapira JD, et al. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971;12(2):245–58.
Milovan D, Almeida L, Romach MK, et al. Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. Epilepsy Behav. 2010;18(4):366–73.
Romach MK, Schoedel KA, Rosen LB, et al. Adverse effects of gaboxadol and zolpidem at high doses in recreational drug users [poster]. 47th Annual Meeting American College of Neuropsychopharmacology, 7–11 Dec 2008, Scottsdale (AZ).
Schoedel KA. Measures of abuse potential in human abuse liability trials: application to anti-epileptics [workshop]. College on Problems of Drug Dependence, 22 June 2009, Reno-Sparks (NV).
Schoedel KA, Rosen LB, Alexander R, et al. A Single-dose, randomized, double-blind, crossover abuse liability study to evaluate the subjective and objective effects of gaboxadol and zolpidem in recreational drug users [poster]. American Society for Clinical Pharmacology and Therapeutics, 18–21 March 2009, National Harbor (MD).
Rush CR, Baker RW, Wright K. Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology (Berl). 1999;144(3):220–33.
Shram MJ, Schoedel KA, Bartlett C, et al. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. Clin Pharmacol Ther. 2011;89(5):683–92.
de Haas S, Dingemanse J, Hoever P, et al. Pseudohallucinations after zolpidem intake: a case report. J Clin Psychopharmacol. 2007;27(6):728–30.
Johanson CE, Balster RL, Henningfield JE, et al. Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report. Drug Alcohol Depend. 2009;105(Suppl 1):S65–71.
Carter LP, Griffiths RR. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend. 2009;105(Suppl 1):S14–25.
Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry. 2006;63(10):1149–57.
Martinotti G, Lupi M, Sarchione F, et al. The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview. Curr Pharm Des. 2013;19(35):6367–74.
Harris GC, Aston-Jones G. Arousal and reward: a dichotomy in orexin function. Trends Neurosci. 2006;29(10):571–7.
Aston-Jones G, Smith RJ, Sartor GC, et al. Lateral hypothalamic orexin/hypocretin neurons: a role in reward-seeking and addiction. Brain Res. 2010;1314:74–90.
Tsujino N, Sakurai T. Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev. 2009;61(2):162–76.
Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011;51:243–66.
Smith RJ, See RE, Aston-Jones G. Orexin/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine-seeking. Eur J Neurosci. 2009;30(3):493–503.
Smith RJ, Aston-Jones G. Orexin/hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking. Eur J Neurosci. 2012;35(5):798–804.
Jupp B, Krstew E, Dezsi G, et al. Discrete cue-conditioned alcohol-seeking after protracted abstinence: pattern of neural activation and involvement of orexin(1) receptors. Br J Pharmacol. 2011;162(4):880–9.
Hollander JA, Pham D, Fowler CD, et al. Hypocretin-1 receptors regulate the reinforcing and reward-enhancing effects of cocaine: pharmacological and behavioral genetics evidence. Front Behav Neurosci. 2012;6:47.
Espana RA, Oleson EB, Locke JL, et al. The hypocretin-orexin system regulates cocaine self-administration via actions on the mesolimbic dopamine system. Eur J Neurosci. 2010;31(2):336–48.
Borgland SL, Chang SJ, Bowers MS, et al. Orexin A/hypocretin-1 selectively promotes motivation for positive reinforcers. J Neurosci. 2009;29(36):11215–25.
Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron. 2003;38(5):715–30.
Dugovic C, Shelton JE, Aluisio LE, et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther. 2009;330(1):142–51.
Salamone JD, Correa M. The mysterious motivational functions of mesolimbic dopamine. Neuron. 2012;76(3):470–85.
Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1):217–38. doi:10.1038/npp.2009.110.
Lena I, Parrot S, Deschaux O, et al. Variations in extracellular levels of dopamine, noradrenaline, glutamate, and aspartate across the sleep–wake cycle in the medial prefrontal cortex and nucleus accumbens of freely moving rats. J Neurosci Res. 2005;81(6):891–9.
Hoever P, de Haas S, Winkler J, et al. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther. 2010;87(5):593–600.
Acknowledgments
The authors thank the subjects and investigators who took part in this study. The authors received administrative support from Jorge Campos (Actelion Pharmaceuticals Ltd) for preparing the manuscript.
Funding
This study was sponsored by Actelion Pharmaceuticals Ltd, Switzerland, which provided payments to investigators or their institutions to perform the study.
Conflicts of Interest
Hans Cruz, Petra Hoever, and Jasper Dingemanse are full-time employees of, and own stock options in Actelion Pharmaceuticals Ltd. Edward M. Sellers, the principal investigator of the study, Bijan Chakraborty, the study statistician, and Kerri Schoedel, the scientific advisor, were full-time employees of INC Research Toronto Inc. (previously Kendle Early Stage, Toronto, ON, Canada) at the time of the study. Payments were received from their institutions and from Actelion Pharmaceuticals Ltd for performing the study and for data analysis.
Author Contributions
Hans Cruz wrote the manuscript, designed research, and analyzed data. Petra Hoever wrote the manuscript, designed research, and analyzed data. Jasper Dingemanse wrote the manuscript, designed research, and analyzed data. Edward M. Sellers wrote the manuscript, designed and performed research, analyzed data, and contributed new reagents/analytical tools. Bijan Chakraborty wrote the manuscript, designed research, and analyzed data. Kerri Schoedel wrote the manuscript, designed research, and analyzed data.
Author information
Authors and Affiliations
Corresponding author
Additional information
ClinicalTrials.gov registration number: NCT01987739.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Cruz, H.G., Hoever, P., Chakraborty, B. et al. Assessment of the Abuse Liability of a Dual Orexin Receptor Antagonist: A Crossover Study of Almorexant and Zolpidem in Recreational Drug Users. CNS Drugs 28, 361–372 (2014). https://doi.org/10.1007/s40263-014-0150-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40263-014-0150-x